ZFGN Zafgen, Inc. gains 46% Jan 29, 2018

Posted By: Rajesh Srivastava - Monday, January 29, 2018

Share

& Comment

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company's lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts. http://www.priceseries.com/trade/ZFGN-Zafgen-Inc-stock-gains-46-percent-a-Trade-Record-by-priceSeries-2017122020180129.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.